Beiersdorf acquires microbiome company S-Biomedic

By

Benjamin Fitzgerald

Published
Dec 19, 2022

German cosmetics giant Beiersdorf announced on Friday it has acquired a majority stake in S-Biomedic NV, a life-science company and leader in the field of skin microbiome research.

Under the agreement, Belgium-based S-Biomedic will continue to be managed as a standalone entity under Beiersdorf’s existing microbiome program and will add to the Hamburg-based company’s own research activities in this field. The purchase price was not disclosed.

“As skin care experts, research has been at the heart of what we have been doing for 140 years. Therefore, the acquisition of S-Biomedic is an ideal strategic fit to drive our innovation power even further in line with our 'C.A.R.E.+' strategy," said Dr. Gitta Neufang, senior vice president of research and development at Beiersdorf.

Ads

"Together with the pioneers of S-Biomedic we are taking skin care to the next level and will foster the development of solutions for unmet consumer needs."

The acquisition follows Beiersdorf's initial ​investment in S-Biomedic in 2018, with the company added it "recognised the potential of the skin microbiome for skin care early on."

​Founded by Veronika Oudova and Bernhard Paetzold in 2014, S-Biomedic researches the balance of the skin’s microbiome and develops active ingredients for cosmetic products by making use of living skin bacteria.

"​Our vision since 2014 when we started S-Biomedic has been to build and promote skin microbiome technologies and make them to the new frontier in skin health," said Veronika Oudova, CEO of S-Biomedic.

"I am very excited that together with the team we have achieved a very important milestone on that journey. By joining Beiersdorf our novel approach has its path to consumers all over the world."